GmmaTech

Interpace Diagnostics Group stock (IDXG) is down: expect recover

NASDAQ:IDXG   None
There are some positive commercial developments for the company. The mega-insurer Cigna stated it will cover ThyraMIR, a microRNA gene expression classifier for thyroid nodules, that Interpace Diagnostics developed.

The health insurer has covered another IDXG's drug ThyGenX since 2017. 80% of ThyGenX orders are coupled with an order for ThyraMIR, and the two tests are billed independently.

www.finstead.com/bit...diction-july-25-2018


Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.